Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Anti-IL-23 Guselkumab Phase III-Ready After Solid Psoriasis Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Specific interleukin-23 blocker meets primary endpoint in Phase IIb dose-ranging study, paving the way for pivotal trials.

You may also be interested in...



J&J’s Solid Launches Lead Strong Pharma Segment Quarter

Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.

J&J Highlights Late-Stage R&D Prospects Across Pharma Division

J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.

Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel